Mediclinic International plc provided Group earnings guidance for the year ended March 31, 2018. The Group expects to deliver adjusted financial results for the year marginally ahead of expectations, with a significant second half improvement from the Middle East division. In constant currency, fiscal 2018 revenue is expected to be up around 2% and adjusted EBITDA flat on the prior year. However, after the translation effect of foreign currency movements, fiscal 2018 revenue is expected to be up around 4% at GBP 2.9 billion (first half 2017: GBP 2.7 billion) and adjusted EBITDA up around 3% at GBP 0.5 billion (first half 2017: GBP 0.5 billion). Adjusted earnings per share, impacted by the equity accounted share of reported profit after tax from Spire, is expected to be broadly flat on the prior year (first half 2017: 29.8 pence). In line with the requirements of IFRS, the Group performs an annual review of the carrying value for goodwill and other intangible assets. In Switzerland, the changes in the market and regulatory environment have affected key inputs to the ongoing year-end review that could potentially give rise to an impairment charge against intangible assets of GBP 400 million to GBP 600 million. Hirslanden goodwill and indefinite life trade names were carried at £307 million and £341 million, respectively, at the previous year end balance sheet date of 31 March 2017. Any potential impairment charge will be non-cash and excluded from the adjusted earnings metrics.